Sym004, a novel anti-EGFR antibody mixture augments radiation response in human lung and head and neck cancer models

被引：0

作者：

Huang, Shyhmin ^{[1
]}

Armstrong, Eric A. ^{[1
]}

Kragh, Michael ^{[2
]}

Pedersen, Mikkel W. ^{[2
]}

Harari, Paul M. ^{[1
]}

机构：

[1] Univ Wisconsin, Madison, WI USA

[2] Symphogen AS, Lyngby, Denmark

来源：

CANCER RESEARCH | 2012年 / 72卷

关键词：

D O I：

10.1158/1538-7445.AM2012-2720

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2720

引用

页数：2

共 50 条

[31] Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses A Phase 2 Randomized Clinical Trial
Montagut, Clara
Argiles, Guillem
Ciardiello, Fortunato
Poulsen, Thomas T.
Dienstmann, Rodrigo
Kragh, Michael
Kopetz, Scott
Lindsted, Trine
Ding, Cliff
Vidal, Joana
Clausell-Tormos, Jenifer
Siravegna, Giulia
Sanchez-Martin, Francisco J.
Koefoed, Klaus
Pedersen, Mikkel W.
Grandal, Michael M.
Dvorkin, Mikhail
Wyrwicz, Lucjan
Rovira, Ana
Cubillo, Antonio
Salazar, Ramon
Desseigne, Francoise
Nadal, Cristina
Albanell, Joan
Zagonel, Vittorina
Siena, Salvatore
Fumi, Guglielmo
Rospo, Giuseppe
Nadler, Paul
Horak, Ivan D.
Bardelli, Alberto
Tabernero, Josep
JAMA ONCOLOGY, 2018, 4 (04)
[32] A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Hou, M. M.
Ho, C. L.
Lin, H. Y.
Jiang, W.
Liu, S.
Hong, Y.
Luk, A.
Lin, S. F.
Hsieh, T. C.
Liu, E.
ANNALS OF ONCOLOGY, 2019, 30
[33] Novel anti-EGFR scFv human antibody-conjugated immunoliposomes enhance chemotherapeutic efficacy in squamous cell carcinoma of head and neck
Wang, Yi-Ping
Liu, I-Ju
Chung, Meng-Jhe
Wu, Han-Chung
ORAL ONCOLOGY, 2020, 106
[34] Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?
Bossi, Paolo
Siano, Marco
Bergamini, Cristiana
Rocca, Maria Cossu
Sponghini, Andrea P.
Giannoccaro, Marco
Tonella, Luca
Paoli, Alessandro
Marchesi, Edoardo
Perrone, Federica
Pilotti, Silvana
Locati, Laura D.
Canevari, Silvana
Licitra, Lisa
De Cecco, Loris
DISEASE MARKERS, 2017, 2017
[35] Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients
Trivedi, Sumita
Srivastava, Raghvendra M.
Concha-Benavente, Fernando
Ferrone, Soldano
Garcia-Bates, Tatiana M.
Li, Jing
Ferris, Robert L.
CLINICAL CANCER RESEARCH, 2016, 22 (21) : 5229 - 5237
[36] DULIGOTUZUMAB Human anti-EGFR/anti-HER3 MAb Colorectal cancer therapy Head and neck cancer therapy
Cole, P.
DRUGS OF THE FUTURE, 2015, 40 (03) : 167 - 172
[37] ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models
Kang, Han Na
Kim, Se-Ho
Yun, Mi Ran
Kim, Hye Ryun
Lim, Sun Min
Kim, Min-Soo
Hong, Kwang-Won
Kim, Sung-Moo
Kim, Hwan
Pyo, Kyoung-Ho
Park, Hye Ji
Han, Joo Yeun
Youn, Hyun A.
Chang, Ki-Hwan
Cho, Byoung Chul
LUNG CANCER, 2016, 95 : 57 - 64
[38] ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models
Cho, B. C.
ANNALS OF ONCOLOGY, 2015, 26 : 38 - 38
[39] Switching anti-EGFR antibody re-sensitizes head and neck cancer patient following acquired resistance to cetuximab
Khattri, Arun
Sheikh, Nizamuddin
Agrawal, Nikhil
Kaushik, Sandeep
Kochanny, Sara
Ginat, Daniel
Lingen, Mark W.
Blair, Elizabeth
Seiwert, Tanguy Y.
CANCER GENE THERAPY, 2024, 31 (10) : 1477 - 1485
[40] HER3 pathway analysis in radiation plus concurrent cisplatin or anti-EGFR moAb for head and neck cancer
Benavente, S.
Cerezo, L.
De la Torre, A.
Contreras, J.
Semidey, M.
Alberola, M.
Hernandez, J.
Giralt, J.
RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S205 - S205

← 1 2 3 4 5 →